Clinical trials: Neuroendocrine Tumor Metastatic
Neuroendocrine Carcinoma, Breast Cancer
Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans
The primary objective of the trial is to test the new radio tracer 68Ga-NODAGA-E[c(RGDyK)]2 for PET imaging of angiogenesis. The tracer has the potential of identifying tumors with a high level of angiogenesis, which is one of…
- Conditions
- Neuroendocrine Carcinoma, Breast Cancer, Ovarian Cancer
- Trial name
- NCT02970786
- Testing
- Injection of 68Ga-NODAGA-E(c[RGDyK])2
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Metastatic Melanoma
Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis
Currently, therapeutic options in BRAF mutated melanoma with brain metastasis occurring after achievement of a good control of extracerebral secondary lesions by a first line combined targeted therapy (TT) are limited.
- Trial name
- NCT05510466
- Where
- France
- Volunteers
- 18 people
- Sponsor
- University Hospital, Montpellier
Solid Tumors
A Study of DF6002 Alone and in Combination With Nivolumab
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
- Trial name
- NCT04423029
- Testing
- DF6002, Nivolumab
- Where
- 32 sites in United States, Australia and 2 more
- Volunteers
- 170 people
- Sponsor
- Dragonfly Therapeutics
Neuroendocrine Tumors
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom response are eligible to enroll in this rollover study to continue once every three weeks fosbretabulin infusions for up to one year.
- Trial name
- NCT02279602
- Testing
- fosbretabulin
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mateon Therapeutics
Recurrent Melanoma, Stage IV Melanoma
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Vaccines may make the body build an immune response to kill tumor cells. Injecting a vaccine directly into a tumor may cause a stronger immune response and kill more tumor cells.
- Trial name
- NCT00087373
- Testing
- recombinant fowlpox-TRICOM vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma, Renal Cell Carcinoma
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
The objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma
- Trial name
- NCT05661955
- Testing
- BGB-A445, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 113 people
- Sponsor
- BeiGene
Metastatic Melanoma
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
In this randomized controlled phase III study the investigators will evaluate whether TIL infusion preceded by non-myeloablative chemotherapy and followed by high dose bolus interleukin-2 can result in an improved progression…
- Trial name
- TIL (NCT02278887)
- Testing
- Translational research, Cyclophosphamide, Fludarabine
- Where
- 2 sites in Denmark, Netherlands
- Volunteers
- 168 people
- Sponsor
- The Netherlands Cancer Institute
Stage IV Skin Melanoma, Eye; Melanoma
Study With T-cel Receptor Gene Therapy in Metastatic Melanoma
Patients with stage IV melanoma (also eye melanoma) will be treated with TCR transduced cells.
- Trial name
- TCR (NCT02654821)
- Testing
- TCR transduced T-cells, Biopsy, Blood taking
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- The Netherlands Cancer Institute
Melanoma
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
This study aims to compare real-world effectiveness of BRAF/MEK inhibitors in BRAF-mutant metastatic melanoma patients in the United States by line of therapy.
- Trial name
- OCEANMIST (NCT05260684)
- Testing
- Encorafenib, Binimetinib, Vemurafenib
- Where
- United States
- Volunteers
- 716 people
- Sponsor
- Pfizer
Thyroid Carcinoma
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid…
- Trial name
- NCT02114658
- Testing
- Sorafenib (Nexavar,BAY43-9006)
- Where
- 5 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Bayer
Melanoma, Cutaneous Malignant, Mucosal Melanoma
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the…
- Trial name
- SUPRAME (NCT06743126)
- Testing
- IMA203, nivolumab plus relatlimab, lifileucel
- Where
- 71 sites in United States, Canada and 4 more
- Volunteers
- 450 people
- Sponsor
- Immatics US, Inc.
Melanoma
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
The purpose of this study is to learn about the effects of 3 study medicines (encorafenib, binimetinib, pembrolizumab) compared to 2 study medicines (ipilimumab and nivolumab) given for the treatment of melanoma.
- Trial name
- PORTSIDE (NCT05926960)
- Testing
- encorafenib, binimetinib, pembrolizumab
- Where
- 24 sites in Germany, Italy and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Metastatic Melanoma
Radiation and Combination Immunotherapy for Melanoma
This is a Phase 2 study designed to evaluate the combination of checkpoint blockade and aldesleukin (IL-2) therapy after a course of standard of care palliative radiation in the management of unresectable metastatic melanoma.
- Trial name
- NCT03850691
- Testing
- Aldesleukin: All Patients, Nivolumab: Cohort 1 (Cutaneous), Nivolumab: Cohort 2 (Ocular)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Sarcoma, Melanoma
Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
This is a Phase 1b, open label, multi-center study of CMB305 (sequentially administered LV305 [a dendritic cell-targeting viral vector expressing the NY-ESO-1 gene] and G305 [NY-ESO-1 recombinant protein plus GLA-SE]) in patients…
- Conditions
- Sarcoma, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer
- Trial name
- NCT02387125
- Testing
- CMB305, G100, Metronomic CPA
- Where
- 8 sites in United States
- Volunteers
- 79 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Metastatic Melanoma, Stage III Melanoma
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
To evaluate the preliminary efficacy of the established dose of indoximod in combination with immune checkpoint inhibition as measured by the best overall response rate (ORR) (complete response (CR) + partial response (PR))across…
- Conditions
- Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
- Trial name
- NCT02073123
- Testing
- Indoximod, Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 131 people
- Sponsor
- NewLink Genetics Corporation
Neuroendocrine Carcinoma, Islet Cell Carcinoma
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Objectives: Primary endpoint: -Assess the clinical activity of RAD 001 plus depot octreotide as defined by progression free survival (PFS) duration defined by RECIST criteria in treated and untreated patients with metastatic…
- Trial name
- NCT00113360
- Testing
- RAD001, Octreotide Depot
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing.
- Trial name
- NCT00004141
- Testing
- Cisplatin, dacarbazine, Granulocyte-macrophage colony-stimulating factor
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Chicago
Locally Advanced Solid Tumor, Metastatic Cancer
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT03881488
- Testing
- CTX-471, Pembrolizumab (KEYTRUDA®)
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Compass Therapeutics
Metastatic Melanoma
Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma
The aim of this research project is to determine whether a short bout of physical exercise immediately before the start of immunotherapy (Nivolumab and Ipilimumab) is feasible and has a positive effect on the effectiveness of…
- Trial name
- SPRINT (NCT07564570)
- Testing
- 30 Minutes Cycle Ergometer
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Melanoma, Brain Metastases
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Dabrafenib and trametinib are drugs that are usually given for the treatment of melanoma. Combinations of dabrafenib and trametinib have also been studied and when used together have shown to increase tumour shrinkage in animals…
- Trial name
- NCT02974803
- Testing
- Dabrafenib, Trametinib
- Where
- 6 sites in Canada
- Volunteers
- 6 people
- Sponsor
- Canadian Cancer Trials Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.